Abstract: A biologic matrix comprises a three-dimensional, resorbable collagen scaffold derived from a vascularized portion of a perfusion-decellularized, suspension-dried mammalian organ or tissue. The scaffold features a porous structure with a plurality of interconnected pores originating from one or more of its outer surfaces. The pores are created by forcing a gas through the vascular pathways of the mammalian organ or tissue while it is in a suspended position. This enables the gas to inflate the vascular pathways in all directions without restriction. The porous configuration substantially enhances the scaffold's effective surface area, making it at least 10 times greater than that of a non-porous scaffold having equivalent outer dimensions. In certain embodiments, the surface area considering the interconnected pores can be 15 times larger or more than the non-porous scaffold of equivalent outer dimensions.

Abstract: Transdermal delivery devices (TDDs) that provide an easy-to-use method of delivering a consistent, steady dose of cannabidiol (CBD) are shown and described herein. The TDDs include a backing layer coated with a mixture of CBD, a polyisobutene adhesive, and plasticizer. Methods of making and using the same are also described.

Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.

Abstract: The present disclosure relates to a method for treating a bone defect using a bio-material with increased porosity and reabsorption characteristics, the method comprising: (a) mixing a dry potassium phosphate based mixture with an aqueous solution to form a reabsorbable bio-material slurry, wherein the dry potassium phosphate based mixture comprises MgO, monobasic potassium phosphate, monobasic sodium phosphate, proteoglycans, and calcium sodium phosphosilicate, wherein a weight percent ratio of monobasic potassium phosphate to MgO is between about 3:1 and 1:1, wherein the dry potassium phosphate based mixture is configured to be mixed with the aqueous solution to thereby form a reabsorbable bio-material slurry, wherein the proteoglycans are between about 1-10 weight percent of the dry composition, (b) accessing a void of a bone defect within a bone, and (c) filling the void with the reabsorbable bio-material slurry, wherein the reabsorbable bio-material slurry is osteoconductive and osteoinductive, thereby e

Abstract: Provided is a method for manufacturing a ring-shaped bone grafting substitute. The method for manufacturing a ring-shaped bone grafting substitute includes a biodegradable polymer providing step of providing a biodegradable polymer, a molding material providing step of providing a molding material in which the biodegradable polymer and a bone material are mixed; a molding material injection step of injecting the molding material into a ring-shaped mold such that a hole is formed in the center thereof; and ring-shaped bone grafting substitute molding step of freeze-drying the molding material having been injected into the ring-shaped mold at a temperature lower than a predetermined reference temperature, thereby molding the resultant into a ring-shaped bone grafting substitute.

Abstract: An osteoinductive and osteoconductive composition including DBM fibers having multiple geometries, as well as a method of producing the same are disclose. For example, such a method may include: obtaining bone tissue; cleaning the bone tissue obtained with a plurality of washes; milling the cleaned bone tissue into a plurality of fibers of two or more geometries including a long wide fiber, a long narrow fiber, a short wide fiber, and a short narrow fiber; demineralizing the plurality of fibers of two or more geometries to expose one or more biologically active components; and neutralizing the plurality of demineralized fibers of two or more geometries resulting in demineralized bone matrix.

Abstract: A bone implant for enclosing bone material is provided. The bone implant comprises a covering, which can be a biodegradable mesh. The covering is configured to be rolled into a diameter to at least partially enclose the bone material within the covering. In some embodiments, the covering includes a body portion and a closure portion adjacent to the body portion. The closure portion is configured to hold the covering in a rolled configuration to a predetermined diameter to at least partially enclose the bone material. A kit and a method of using the bone implant are also provided.

Abstract: The present disclosure relates aqueous composition comprising a mucoadhesive polymer and clay particles and methods of treating or preventing infection.

Abstract: The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided.

Abstract: This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSC) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteoradionecrosis.

Abstract: Disclosed is a bioresorbable implant with enhanced bone ingrowth and tissue integration utilizing an inside-out resorption mechanism and a method to manufacture a bioresorbable implants for use in osteotomies and bone-soft tissue reconstruction surgeries. The bioresorbable implant includes a polymer A (e.g., an aliphatic polymer matrix) and/or poly(propylene fumarate)), a carbohydrate B (e.g., a bioresorbable natural carbohydrate filler) and a ceramic C. The implant may be a porous scaffold structures with suitable porosity, pore size, pore interconnectivity, and mechanical properties for enhanced osteoblast penetration and bone formation to fabricate tissue integrating bioresorbable implants. The implant may be shaped as wedges, bone void fillers, and soft tissue fixation implant like screws, rods and/or anchors. In some embodiments, the implant may be a putty.

Abstract: The disclosure relates to an expandable scaffold and a method for fabricating the scaffold. The expandable scaffold includes a three-dimensional porous structure comprising a composite material composed by a first material and a second material. The 3D porous structure has a tunable expansion capacity. When applied in a liquid, the 3D porous structure may uptake the liquid and expand from an original volume to an expansion volume up to 1000 times of the original volume. The 3D porous structure may be formed by a plurality of layers of the composite material, and architecture and shape of the layers of the composite material are arranged in accordance with a shape and a size of the expansion volume. Applications of the scaffold may include a bone or soft tissue regeneration system or a bleed stopping device.

Abstract: The present invention relates to the field of treatment of bone defects. The invention provides a composition for treatment of bone defects as well as methods for treatment of such defects.

Abstract: The present disclosure provides a medical adhesive and a preparation method thereof, comprising a component A and a component B: the component A comprises a cycloketene acetal compound and an oxidizing agent; the component B comprises a vinyl monomer, a cross-linking agent and a reducing agent, wherein the cycloketene acetal compound is selected from one or more of 2-methylene-1,3-dioxepane, 2-methylene-4-phenyl-1,3-dioxolane, 5,6-benzo-2-methylene-1,3-dioxepane and 4,7-dimethyl-2-methylene-1,3-dioxepane. The medical adhesive overcomes the disadvantages of conventional medical adhesives.

Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having at least one coating made at least in part using printing technologies to provide drug storage and drug release structures, notably for hydrophobic drugs and that such hydrophobic drugs can be stabilized as to hydrolysis, heat, and a combination thereof. A first aspect of the present invention includes a packaged medical device that includes at least one drug delivery contact lens. A second aspect of the present invention includes a drug delivery contact lens. A third aspect of the present invention includes a method of making a drug delivery contact lens. A fourth aspect of the present invention includes an ink. A fifth aspect of the present invention includes a method of using a drug delivery contact lens to treat or prevent a disease, disorder, or condition of the eye.

Abstract: A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.

Abstract: An inflated and suspension dried decellularized extracellular matrix of a mammalian organ or tissue, or a vascularized portion thereof, and methods of making and using the inflated and suspension dried material, are provided.

Abstract: The present application describes a method of treating neuropathic pain in a patient. The method includes a step of administering a pharmaceutical composition to the patient. The pharmaceutical composition consists of one or more pharmaceutically acceptable excipients, Palmitoylethanolamide (PEA) ranging from 35 to 80% by weight, one or more naturally occurring Fatty Acid Amide Hydrolase (FAAH) Inhibitors ranging from 0.5 to 40% by weight, and optionally a vitamin and/or a co-enzyme. The combination of PEA and the one or more naturally occurring FAAH inhibitors in the administered pharmaceutical composition act synergistically to reduce neuropathic pain in the patient.

Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.

Abstract: A method for augmenting a void or treating a wound in a body cavity involves applying a three-dimensional, resorbable collagen scaffold derived from a vascularized portion of a perfusion-decellularized mammalian tissue or organ to the site of the void or body cavity. The scaffold can be applied to the site of the void or body cavity in a way that ensures at least three surfaces or five surfaces of the scaffold come into contact with the surrounding body tissue. The scaffold contains numerous pores, resulting in a larger surface area compared to a scaffold without pores of the same outer dimensions. Additionally, the method includes releasing an antimicrobial agent into the surrounding body tissue to inhibit infection. The antimicrobial agent, such as silver nanoparticles, methylene blue, or iodine-based compounds, is perfused into the scaffold's vascular pathways following its perfusion decellularization.